GenSight Biologics Appoints Elsy Boglioli to its Board of Directors

Cell & Gene Meeting on the Mesa – Virtual

HealthTech Innovation Days (HTID®), Paris, France & Virtual Conference

Ophthalmology Futures Retina – Virtual Forum

Chardan 4th Annual Genetic Medicines Conference – Virtual

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors